Wikipedia -WSS

Wikipedia

author：hotspot 2025-09-27 23:00:32 - browse：5

Stock illustration of computer and medication — Adobe

Digital therapeutics company Click Therapeutics announced Wednesday it will acquire the assets of Better Therapeutics, developer of a software-based treatment for diabetes. Click, which did not disclose how much it is paying for the assets, hopes to adapt Better’s tech for use alongside GLP-1 medications.

Better Therapeutics announced in March that it was delisting from the Nasdaq stock exchange and shutting down operations as it sought strategic alternatives. The company had been, since last year, searching for ways to stay afloat as its cash reserves dwindled.

Last, year, Better received Food and Drug Administration clearance for AspyreRx, a prescription app that delivers cognitive behavioral therapy and had been shown to reduce A1c levels in people with type 2 diabetes. Still, the company has been unable to ramp up significant commercial traction. Better also had a pipeline of other products targeting cardiometabolic conditions, and had made early claims about the benefits of AspyreRx in people taking GLP-1s for diabetes management.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Why the world’s most expensive drug might be worth the price

WSS

Merck drug for rare lung condition set for approval in U.S.

Eliminate the waiting period for sterilization covered by Medicaid

Readout Newsletter: Blackstone Life Sciences, Merck, Bluebird Bio

Study says nonprofit hospitals fall short in charity care spending

Will biotech layoffs continue through 2023?

Timeline: Special counsel's probe into Trump's handling of classified documents

knowledge

Wikipedia

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

leisure time

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

American Airlines has a tentative contract deal with its pilots. Southwest is still negotiating

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Abortion pill Supreme Court ruling could impact entire drug industry

Alkermes shareholders re

States should stop sabotaging methadone treatment reform

Sports medicine is finally prioritizing gender equality

'The boss' wants server deleted: New allegations emerge in Trump indictment

Jerome Adams on the need for new antivirals for Covid

Eliminate the waiting period for sterilization covered by Medicaid

focus

Will generative AI in health care meet the fate of IBM's Dr. Watson?

Behind warning on Apellis’s eye drug lies a conflict of interest

Interest rates are at a 22

Donor acceptance rates hint at racial, gender bias in heart transplants: study

States should stop sabotaging methadone treatment reform

Readout LOUD podcast: mifepristone case, GLP

leisure time

focus

Wikipedia

Wikipedia